1.	STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STARS-Pilot (05/55 Graham), NCT00126360
2.	Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
3.	Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: N07MAN, Eudract 2007-007030-20, NCT00684216
4.	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 0120070323, NCT00698971
5.	Phase III Randomized Study of Adjuvant Tamoxifen Versus Anastrozole in Postmenopausal Women With Ductal Carcinoma In Situ Phase: Phase III Type: Treatment Status: Active Age: 40 to 70 Sponsor: Other Protocol IDs: CRUK-IBIS-II-DCIS, EU-20226, BIG-5-02, NCT00072462, IBCSG-31-03-DCIS, ISRCTN31488319
6.	Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment Phase: Phase III Type: Supportive care, Treatment Status: Active Age: Postmenopausal Sponsor: Other Protocol IDs: ALCC 04.02, NCT00122356
7.	Aromasin vs Arimidex Study As Initial Hormonal Therapy in Postmenopausal Women With Advanced/Recurrent Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5991048, NCT00143390
8.	Phase III Randomized Study of Fulvestrant With Versus Without Anastrozole Versus Exemestane Alone in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Relapsed or Progressed During Prior Treatment With Nonsteroidal Aromatase Inhibitors Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
9.	Assessing Impact of Loco-Regional Treatment on Survival in Metastatic Breast Cancer at Presentation Phase: Phase III Type: Treatment Status: Active Age: 21 to 65 Sponsor: Other Protocol IDs: TMH/153/2004, NCT00193778
10.	Secondary Adjuvant Long Term Study With Arimidex Phase: Phase III Type: Treatment Status: Active Age: 80 and under Sponsor: Pharmaceutical / Industry Protocol IDs: 1033AU/0003, ABCSG 16, D5392L00016, SALSA, NCT00295620
11.	Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial) Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: ECOG-PACCT-1, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
12.	Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: GIM-3-FATA, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086
13.	Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GEICAM/2006-10, NCT00543127
14.	Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment Phase: Phase III Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D539BC00001, NCT00605267
15.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
16.	Phase III Randomized Study of Adjuvant Endocrine Therapy Comprising Letrozole, Anastrazole, or Exemestane Versus Tamoxifen Citrate in Postmenopausal Women With Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Under 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: COL-MNEMOSYNE, MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, NCT00893061
17.	STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing) Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: TROG 08.06, NCT00887380
18.	Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Other Protocol IDs: SHBCC0701, NCT00902954
19.	Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238UK/0005, NCT00944918
20.	Phase I/II Study of Sorafenib in Combination With Anastrozole in Postmenopausal Women With Estrogen Receptor- and/or Progesterone Receptor-Positive Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GUMC-2004-251, 6584, NCI-6584, NCT00217399
21.	Chemoprevention Trial - Anastrozole in DCIS in Postmenopausal Women Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCI 03-16, NCT00256217
22.	Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: JBCRN-06, UMIN000000610, NCT00437359
23.	Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BRSADJ0008, 97923, BRSADJ0008, NCT00481845, NCT00481845
24.	Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure Phase: Phase II Type: Treatment Status: Active Age: 18 to 50 Sponsor: Other Protocol IDs: UMCC 2007.044, NCT00555477
25.	Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H 20431, PACT 001, NCT00570323